Advisors

Dale L. Barnard Ph.D.

Dr. Barnard's principle research at Utah State University has been in antiviral chemotherapy and toxicology, both in antiviral screening and in secondary in vivo antiviral studies supported by National Institutes of Health, the U.S. Army Medical Institute, and various pharmaceutical companies. Current research focuses on developing treatments for SARS-CoV, influenza H5N1, and viruses of biodefense importance. Dr. Barnard is internationally recognized with over 60 research publications.

Honors and Awards:

President, Intermountain Branch American Society for Microbiology, 1995-1996, 2001-2002
Mortar Board Top Professor for 1999-2000
Top Professor and International Student Council Professor of the Year, Utah State University, 2000
Joe E. Whitesides Scholar-Athlete Recognition Award for the year 2001
Invited speaker, 2nd International conference on Community Acquired Pneumonia, 2005

Email: dale.barnard@usu.edu

Richard Horuk Ph.D.

Dr. Horuk has 20+ years of experience in R&D in the biotechnology and pharmaceutical industry. For three years he served as Director of Immunology at Berlex Biosciences, leading a group of 28 people. He has experience in taking drugs from concept to phase II clinical trials. A recent focus of his work has been to identify novel therapeutics that target G-protein coupled receptors to treat immunological disorders such as multiple sclerosis. Dr. Horuk has an excellent track record of achievement in drug discovery from the bench to the clinic. Dr. Horuk has served as an Editor for the Journal of Biological Chemistry and his scientific accomplishments are internationally recognized with over 160 publications.

Email: horuk@pacbell.net

John Parkinson Ph.D.

Dr. Parkinson has 17+ years biotechnology / pharma R&D experience in Cardiovascular and Immunology Research at Berlex Laboratories / Schering AG and at Bayer Schering Pharmaceuticals. He led successful drug optimization programs in selective inducible nitric oxide synthase inhibitors (licensed to Pfizer in 2003), lipoxin analogs (currently in phase I human studies) and LTA4-h inhibitors. Dr. Parkinson is internationally recognized with over 60 research publications and is an inventor on over 20 patents. Dr. Parkinson did postgraduate training in Biochemistry at the University of Bristol (UK) and fellowships in hematology at Indiana University (Indianapolis, USA) and thrombosis research at Lilly Laboratories (Indianapolis, USA).

Email: j2p2@earthlink.net